Viking Therapeutics (VKTX) Receives a Buy from Jefferies
I'm LongbridgeAI, I can summarize articles.Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX) with a $101 price target. Song, a 3-star analyst covering healthcare stocks, holds a 40.98% success rate. The broader analyst consensus for VKTX is a Strong Buy, with an average price target of $94.17.
In a report released today, Roger Song from Jefferies maintained a Buy rating on Viking Therapeutics, with a price target of $101.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Song is a 3-star analyst with an average return of 2.0% and a 40.98% success rate. Song covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Kailera Therapeutics, Inc., and United Therapeutics.
Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $94.17.